These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25462534)

  • 1. Emerging therapeutic strategies in COPD.
    Babu KS; Morjaria JB
    Drug Discov Today; 2015 Mar; 20(3):371-9. PubMed ID: 25462534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
    Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
    Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.
    Contoli M; Corsico AG; Santus P; Di Marco F; Braido F; Rogliani P; Calzetta L; Scichilone N
    COPD; 2017 Dec; 14(6):641-647. PubMed ID: 29116901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
    Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.
    Wilkie M; Finch S; Schembri S
    COPD; 2015; 12(5):582-90. PubMed ID: 25774769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on LAMA/LABA combinations for COPD.
    Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Rogliani P; Cazzola M
    Expert Opin Pharmacother; 2014 May; 15(7):961-77. PubMed ID: 24669979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The stepwise approach of COPD therapy].
    Watz H; Kirsten A; Greulich T
    Dtsch Med Wochenschr; 2019 Jan; 144(1):15-20. PubMed ID: 30602182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of use of long-acting bronchodilators in patients with COPD: A nationwide follow-up study of new users in New Zealand.
    Parkin L; Barson D; Zeng J; Horsburgh S; Sharples K; Dummer J
    Respirology; 2018 Jun; 23(6):583-592. PubMed ID: 29265705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies.
    Fitzgerald MF; Fox JC
    Drug Discov Today; 2007 Jun; 12(11-12):472-8. PubMed ID: 17532532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M; Molimard M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
    Cave AC; Hurst MM
    Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
    Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D
    Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations.
    Katajisto M; Koskela J; Lindqvist A; Kilpeläinen M; Laitinen T
    Respir Med; 2015 Oct; 109(10):1320-5. PubMed ID: 26298024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA
    Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the role of triple inhaled therapy in COPD?
    Petite SE
    JAAPA; 2019 Oct; 32(10):44-45. PubMed ID: 31567741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated approach to the medical treatment of chronic obstructive pulmonary disease.
    Rosenberg SR; Kalhan R
    Med Clin North Am; 2012 Jul; 96(4):811-26. PubMed ID: 22793946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.
    Buhl R; Criée CP; Kardos P; Vogelmeier CF; Kostikas K; Lossi NS; Worth H
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2557-2568. PubMed ID: 30197512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
    Calzetta L; Matera MG; Cazzola M
    Eur J Pharmacol; 2015 Aug; 761():168-73. PubMed ID: 25981302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.